Table 2.

Second-line phase III trials in advanced HCC

Trial	Principle target of experimental drug	No. of patients	Median OS
Brivanib versus placebo (BRISK-PS)[28]	VEGFR, FGFR	395	9.4 versus 8.2 months HR 0.89 (0.69–1.15], p=0.33
Everolimus versus placebo (EVOLVE-1)[29]	mTOR	546	7.6 versus 7.3 months HR 1.05 (0.86–1.27], p=0.68
Ramucirumab versus placebo (REACH)[30]	VEGFR2	565	9.2 versus 7.6 months HR 0.87 (0.72–1.05], p=0.14

VEGFR=vascular endothelial growth factor receptor; FGFR=fibroblast growth factor receptor; HR=hazard ratio; mTOR=mechanistic target of rapamycin.